nach oben

International Journal of Clinical Oncology

Erschienen in:

01.06.2011 | Original Article

Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer

verfasst von: Filippo Francini, Alessandra Pascucci, Gianluca Bargagli, Edoardo Francini, Raffaele Conca, Salvatora Tindara Miano, Ignazio Martellucci, Cristina Migali, Giuseppe Gotti, Anna Ida Fiaschi, Annunziata Cozzolino, Roberto Petrioli

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to assess the early effects of zoledronic acid (ZOL) and oral ibandronate (IBA) on the bone resorption marker s-CTX (serum C-telopeptide of collagen type I) and the bone formation marker B-ALP (bone-alkaline phosphatase) in patients with bone metastases from non-small cell lung cancer (NSCLC).

Methods

Fifty-five patients with at least one site of bone metastasis secondary to NSCLC were randomly assigned to receive intravenous ZOL 4 mg every 4 weeks, or oral IBA 50 mg/day.

Results

At 1 month of treatment, s-CTX was reduced by 54.8% (95% CI 40.4–59.8%) in the ZOL group (26 evaluable patients) compared with 38.2% (95% CI 29.8–48.7%) in the oral IBA group (27 evaluable patients) (p = 0.03). At 3 months, s-CTX was reduced by 72.6% (95% CI 58.6–71.3%) in the ZOL group, compared with 66.4% (95% CI 54.3–79.5%) in the oral IBA group (p = 0.22). Both bisphosphonates similarly decreased the bone marker B-ALP at 1 month (ZOL 24.7%, 95% CI 3.6–39.5%, and IBA 24.2%, 95% CI 2.8–43.4%) and 3 months (ZOL 28.6%, 95% CI +2.8–43.3%, and IBA 24.2%, 95% CI 3.2–47.4%). Both bisphosphonates were well tolerated.

Conclusion

Considering the changes in bone markers, ZOL and oral IBA show comparable efficacy in patients with NSCLC and bone metastases.

Clezardin P, Teti A (2007) Bone metastasis. Clin Exp Metastasis 24:599–608PubMedCrossRef

Coleman RE, Purohit OP, Vinholes JJ et al (1997) High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 80(Suppl 8):1686–1690PubMedCrossRef

Lipton A (2003) Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 8:469–488PubMedCrossRef

Cameron D, Fallon M, Diel I (2006) Ibandronate: its role in metastatic breast cancer. Oncologist 11(Suppl 1):27–33PubMedCrossRef

Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558–567PubMed

Berenson JR, Rosen LS, Howell A et al (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191–1200PubMedCrossRef

Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostate Dis 5:231–235CrossRef

Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405PubMedCrossRef

Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133–1137PubMedCrossRef

10.

Francini G, Gonnelli S, Petrioli R et al (1992) Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 10:591–598PubMed

11.

Coleman RE (2002) The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94:2521–2533PubMedCrossRef

12.

Brown JE, Thomson CS, Ellis SP et al (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031–2037PubMedCrossRef

13.

Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925–4935PubMedCrossRef

14.

Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69PubMedCrossRef

15.

Hannon RA, Eastell R (2006) Bone markers and current laboratory assays. Cancer Treat Rev 32(Suppl 1):7–14PubMedCrossRef

16.

Hamaoka T, Madewell JE, Podoloff DA et al (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942–2953PubMedCrossRef

17.

Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1:277–299PubMedCrossRef

18.

De Benedittis G, Massei R, Nobili R et al (1988) The Italian Pain Questionnaire. Pain 33:53–62PubMedCrossRef

19.

McCormack A, Hunter-Smith D, Piotrowski ZH et al (1992) Analgesic use in home hospice cancer patients. J Fam Pract 34:160–164PubMed

20.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:216CrossRef

21.

Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69:1375–1381PubMed

22.

Lipton A (2008) Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34(Suppl 1):S25–S30PubMedCrossRef

23.

Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol 19:420–432PubMedCrossRef

24.

Francini G, Petrioli R, Gonnelli S et al (2001) Urinary calcium excretion in the monitoring of bone metastases. Cancer 92:1468–1474PubMedCrossRef

25.

Kaira R, Murakami H, Kaira K et al (2010) N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. Int J Clin Oncol 15:484–488PubMedCrossRef

26.

Hirsh V, Major PP, Lipton A et al (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3:228–236PubMedCrossRef

27.

Panãres RL, Garcia AA (2007) Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 7:433–445PubMedCrossRef

28.

Smith MR (2006) Markers of bone metabolism in prostate cancer. Cancer Treat Rev 32(Suppl 1):23–26PubMedCrossRef

29.

Lein M, Miller K, Wirth M et al (2009) Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 69:624–632PubMedCrossRef

30.

Body JJ, Lichinitser M, Tjulandin S et al (2007) Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 18:1165–1171PubMedCrossRef

31.

Brown JE, McCloskey EV, Dewar JA et al (2007) The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 81:341–351PubMedCrossRef

32.

Briesacher BA, Andrade SE, Yood RA et al (2007) Consequences of poor compliance with bisphosphonates. Bone 41:882–887PubMedCrossRef

33.

Cramer JA, Gold DT, Silverman SL et al (2007) A systemic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031

34.

Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818PubMedCrossRef

35.

Hochberg MC, Silverman SL, Barr CE et al (2010) The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. J Clin Densitom 13:181–189PubMedCrossRef

36.

Tripathy D, Body JJ, Bergström B (2004) Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 26:1947–1959PubMedCrossRef

Titel: Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer
verfasst von: Filippo Francini
Alessandra Pascucci
Gianluca Bargagli
Edoardo Francini
Raffaele Conca
Salvatora Tindara Miano
Ignazio Martellucci
Cristina Migali
Giuseppe Gotti
Anna Ida Fiaschi
Annunziata Cozzolino
Roberto Petrioli
Publikationsdatum: 01.06.2011
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 3/2011
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0179-x

Springer Medizin

Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer